Cargando…
Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes: A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study
OBJECTIVE: To examine the prevalence and incidence of unrecognized myocardial infarction in a contemporary population with type 2 diabetes. RESEARCH DESIGN AND METHODS: We performed a retrospective analysis of the electrocardiograms (ECGs) recorded at baseline and after 2 years for the first 1,004 t...
Autores principales: | MacDonald, Michael R., Petrie, Mark C., Home, Philip D., Komajda, Michel, Jones, Nigel P., Beck-Nielsen, Henning, Gomis, Ramon, Hanefeld, Markolf, Pocock, Stuart J., Curtis, Paula S., McMurray, John J.V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114348/ https://www.ncbi.nlm.nih.gov/pubmed/21562320 http://dx.doi.org/10.2337/dc10-2398 |
Ejemplares similares
-
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
por: Komajda, Michel, et al.
Publicado: (2010) -
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
por: Komajda, Michel, et al.
Publicado: (2008) -
Rosiglitazone RECORD study: glucose control outcomes at 18 months
por: Home, P D, et al.
Publicado: (2007) -
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes
por: Hanefeld, Markolf
Publicado: (2007) -
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials
por: Home, P. D., et al.
Publicado: (2010)